Sanofi’s Genzyme has licensed rights to develop and commercialise RNAi therapeutics targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis (ATTR) in Japan and other Asia-Pacific territories from Alnylam Pharmaceuticals. The licensed programme includes ALN-TTR02, which reported positive Phase I data in July 2012, and ALN-TTRsc, a subcutaneously administered RNAi therapeutic in late-stage preclinical development. Alnylam will retain rights to develop the programme in the US, Europe and the rest of world.